Onkologie. 2024:18(5):315-317 | DOI: 10.36290/xon.2024.065

Current status of immunotherapy for the pacients with advanced, metastatic and recurent cervical cancer

Helena Kolářová¹, Monika Náležinská^{1, 2}, Josef Chovanec^{1, 2}

Oddělení gynekologické onkologie Kliniky operační onkologie Masarykova onkologického ústavu, Brno

Oddělení gynekologické onkologie Kliniky operační onkologie, Lékařská fakulta Masarykovy univerzity, Brno

Despite the identified etiopathogenesis, primary prevention and national screening program, advanced and metastatic cervical cancer remains a significant clinical problem with limited treatment options. Immunotherapeutics - checkpoint inhibitors enter the treatment portfolio in patients with inoperable locally advanced stages and bring the necessary hope in patients with progressive, metastatic and recurrent cervical cancer in the cohort of fragile, difficult-to-treat patients. The inclusion of immunotherapy in combination with chemotherapy with or without bevacizumab in first-line systemic therapy and in second-line therapy monotherapy following platinum-based chemotherapy resulted in a significant prolongation of overall survival of patients with CC.

Keywords: gynecologic oncology, cervical carcinoma, immunotherapy, checkpoint inhibitors.

Accepted: November 18, 2024; Published: November 28, 2024  Show citation